1 minute read
Dec. 16, 2021

Pemigatinib: a FGFR1/2/3 Kinase Inhibitor

pemigatinib

oral FGFR1/2/3 kinase inhibitor approved in oncology, 13.5 mg QD (14d+, 7d-) from focused screen of ~20k cmpds and SBDD Journal of Medicinal Chemistry Incyte Corporation, Wilmington, US

drughunter.com
Drug Hunter Team
Loading...

twitterlinkedinemail

Other molecules you may be interested in